Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis

BACKGROUND: Ofatumumab is approved for treating relapsing multiple sclerosis (RMS). Examining tolerability will enable understanding of its risk–benefit profile. OBJECTIVE: Report the tolerability profile of ofatumumab in RMS during treatment of up to 4 years and the effect of pre-medication. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Kramer, John, Linker, Ralf, Paling, David, Czaplinski, Adam, Hoffmann, Olaf, Yong, V Wee, Barker, Noreen, Ross, Amy Perrin, Lucassen, Elisabeth, Gufran, Mohammad, Hu, Xixi, Zielman, Ronald, Seifer, Gustavo, Vermersch, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566276/
https://www.ncbi.nlm.nih.gov/pubmed/37829441
http://dx.doi.org/10.1177/20552173231203816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566276/
https://www.ncbi.nlm.nih.gov/pubmed/37829441
http://dx.doi.org/10.1177/20552173231203816

Ejemplares similares